State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.
Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin, People's Republic of China.
Stem Cells Transl Med. 2022 Sep 21;11(9):946-958. doi: 10.1093/stcltm/szac048.
Cord blood hematopoietic stem/progenitor cells (CB-HSPCs) have emerged as a promising supply for functional platelets to potentially alleviate the increasing demand for platelet transfusions, but the clinical application has been limited by the undefined molecular mechanism and insufficient platelet production. Here, we performed single-cell profiling of more than 16 160 cells to construct a dynamic molecular landscape of human megakaryopoiesis from CB-HSPCs, enabling us to uncover, for the first time, cellular heterogeneity and unique features of neonatal megakaryocytes (MKs) and to also offer unique resources for the scientific community. By using this model, we defined the genetic programs underlying the differentiation process from megakaryocyte-erythroid progenitors (MEPs) to MKs via megakaryocyte progenitors (MKPs) and identified inhibitors of euchromatic histone lysine methyltransferase (EHMT), which, when applied at the early stage of differentiation, significantly increase the final platelet production. At the mechanistic level, we found that EHMT inhibitors act to selectively induce the expansion of MEPs and MKPs. Together, we uncover new mechanistic insights into human megakaryopoiesis and provide a novel chemical strategy for future large-scale generation and clinical applications of platelets.
脐带血造血干/祖细胞 (CB-HSPCs) 已成为功能性血小板的有前途的来源,可能缓解日益增长的血小板输注需求,但由于分子机制尚未确定且血小板生成不足,其临床应用受到限制。在这里,我们对超过 16160 个细胞进行了单细胞分析,构建了从 CB-HSPCs 到人类巨核细胞发生的动态分子图谱,使我们能够首次揭示新生儿巨核细胞 (MKs) 的细胞异质性和独特特征,并为科学界提供独特的资源。通过使用该模型,我们定义了从巨核细胞-红细胞祖细胞 (MEPs) 到 MKs 的分化过程背后的遗传程序,途径是巨核细胞祖细胞 (MKPs),并确定了常染色质组蛋白赖氨酸甲基转移酶 (EHMT) 的抑制剂,当在分化的早期阶段应用时,可显著增加最终的血小板产量。在机制水平上,我们发现 EHMT 抑制剂可选择性地诱导 MEPs 和 MKPs 的扩增。总之,我们揭示了人类巨核细胞发生的新机制见解,并为未来血小板的大规模生成和临床应用提供了新的化学策略。